Sysmex Astrego

What Sysmex Astrego does

Sysmex Astrego AB is a Swedish in vitro diagnostics company headquartered in Uppsala, founded in March 2017 as Astrego Diagnostics AB and acquired by Sysmex Corporation, Japan in May 2022. The company develops the PA-100 AST System, a desktop instrument that performs rapid Antibiotic Susceptibility Testing (AST) using proprietary microfluidic single-cell imaging technology originating from Uppsala University's Elf Lab (published in PNAS 2017). The system pairs the analyzer with indication-specific disposable panels preloaded with clinically relevant antibiotics — currently focused on urinary tract infection (UTI) panels with regional antibiotic profiles — and reports presence of growing bacteria within 10 minutes and complete AST results within a 30-minute total turnaround time, compared to several days for conventional methods.

The technology is positioned to address antimicrobial resistance (AMR) by enabling personalized antibiotic prescription at the point of care, targeting both near-patient settings (clinics, primary care) and central laboratories. The pipeline contemplates expansion into respiratory tract infections, tuberculosis, skin infections, and sterile body fluid infections. The company is ISO 13485:2016 certified and received the Longitude Prize on AMR in 2024 as the sole recipient among more than 250 entrants.

Sysmex Astrego operates as a wholly-owned subsidiary of Sysmex Corporation and conducts its go-to-market through Sysmex Europe's established distribution infrastructure — nearly 30 affiliates and over 100 distributors across 110 countries — selling the PA-100 instrument and consumable panels. Revenue is generated through hardware sales of the instrument and recurring sales of indication-specific disposable panels, though no public pricing is disclosed. Marketing activities span the corporate website, LinkedIn, Facebook, YouTube, email newsletter, and participation in EMEA healthcare events.

Name

Sysmex Astrego

Legal name

Sysmex Astrego AB

Website

https://astrego.se

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Sysmex Astrego AB is a Uppsala-based Swedish diagnostics subsidiary of Sysmex Corporation that develops the PA-100 AST System, a microfluidic single-cell imaging platform providing rapid antibiotic susceptibility testing in under 30 minutes for clinicians combating antimicrobial resistance.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)

akta.pro secondary industries

Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC), Antimicrobial Resistance (AMR) & Antibiotic Susceptibility Reference Networks (HLAJAIAF)

Keywords

• Antibiotic susceptibility testing
• Rapid diagnostics
• Antimicrobial resistance
• Microfluidic diagnostics
• Point-of-care testing

Headquarters

HQ city

Uppsala

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. In Vitro Diagnostic Products: Sysmex Astrego generates revenue through the sale of its PA-100 AST System instrument and indication-specific disposable panels for Antibiotic Susceptibility Testing. The company operates as a medical device/diagnostics company serving healthcare providers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Sysmex Astrego develops and sells the PA-100 AST System, a fully automated desktop instrument for rapid Antibiotic Susceptibility Testing (AST) using proprietary microfluidic single-cell imaging technology. The system pairs the analyzer with indication-specific disposable panels (initially focused on urinary tract infections) and delivers bacterial detection within 10 minutes and complete AST results in under 30 minutes, enabling personalized antibiotic prescription at point of care and combating antimicrobial resistance.

Product overview

Sysmex Astrego offers a single unified product system: the PA-100 AST System, which consists of a desktop instrument and indication-specific panels for rapid Antibiotic Susceptibility Testing (AST). The system is designed for near-patient and central laboratory settings, providing automated detection of bacterial infections and susceptibility testing in under 30 minutes. The company is currently focused on urinary tract infection (UTI) panels with regional antibiotic profiles, with expansion planned for respiratory tract infections, tuberculosis, skin infections, and sterile body fluid infections.

Differentiator

Problem solved

Functional benefit

Products and services

• PA-100 AST System A desktop instrument for rapid Antimicrobial Susceptibility Testing (AST) in near-patient and central laboratory settings. The system consists of the analyzer with indication-specific panels and provides AST results in under 30 minutes for conditions including Urinary Tract Infections, Respiratory Tract Infections, Tuberculosis, Skin Infections, and Sterile Body Fluid Infections.
• Indication-Specific AST Panels Disposable panels preloaded with antibiotics relevant for specific infections and geographic regions. Currently developing several panels for UTI testing with region-specific antibiotic profiles for personalized treatment, used with the PA-100 AST System.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

One partnership is on record.

• Sysmex CorporationcoreOthers · 1 May 2022Sysmex Astrego (formerly Astrego Diagnostics AB) was acquired by Sysmex Corporation, Japan in May 2022. Prior to acquisition, Sysmex had invested in Astrego in January 2020, acquiring 24.99% of shares. The acquisition represents Sysmex's strategy to expand into rapid AST diagnostics and primary care testing for urinary tract infections.

Scale indicators1 record

Recent moves7 records

Expansion highlights4 records

Direct peers

• QuantaMatrix: Korean in vitro diagnostics company developing rapid phenotypic AST systems (e.g., QMAC-dRAST), directly competing on the same speed-at-point-of-care axis as Sysmex Astrego's PA-100.
• Accelerate Diagnostics: US-listed infectious disease diagnostics company commercialising rapid phenotypic AST (Accelerate Pheno system), the most direct head-to-head competitor in rapid AST for bloodstream and other infections.

Emerging players

• Specific Diagnostics: Emerging rapid phenotypic AST developer using a different signaling/breath-based modality; targets the same unmet need of same-shift AST for bloodstream and other infections.
• T2 Biosystems: Rapid molecular diagnostics company with T2Bacteria/T2Candida panels for bloodstream infections; competes on the rapid-diagnosis angle rather than on AST specifically, and is most comparable on speed and POC positioning.

Broad incumbents

• bioMérieux: Global IVD incumbent with the VITEK 2 / VITEK MS AST and ID platforms deeply embedded in clinical microbiology labs; represents the core installed-base competitor Sysmex Astrego's central-lab strategy must displace.
• Becton Dickinson (BD): Broad-line microbiology incumbent commercialising the BD Phoenix M50 automated AST system; competes for central-lab AST budgets alongside VITEK and MicroScan.
• Beckman Coulter (Danaher): MicroScan AST line sits within Danaher's diagnostics portfolio; established presence in hospital microbiology labs that Sysmex Astrego may need to displace to win central-lab placements.
• Bruker: MALDI Biotyper for microbial ID is a workflow-adjacent incumbent typically paired with downstream AST; competes in the integrated ID-to-AST clinical value chain Sysmex Astrego also targets.
• ELITech Group: Mid-sized European IVD player offering microbiology AST reagents and instruments; the most regionally comparable competitor within EMEA distribution channels.

Others

• Liofilchem: Italian microbiology consumables manufacturer (AST discs, panels); overlaps with Sysmex Astrego's indication-specific cartridge consumable category and competes indirectly in clinical AST workflows.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/sysmex
• LinkedInlinkedin.com/company/sysmex-europe
• Xx.com/astregodx
• YouTubeyoutube.com/user/SysmexEurope

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sysmex Astrego